Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.53 |
| ▸ | CALCR | P30988 | 4/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 5/20 | 0.50 |
| ▸ | NPY4R | P50391 | 5/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31688311 | 0.93 | CALCR (0.59) | CALCRLSLC6A2CALCRF2NPY2R | |
| SCHEMBL30906521 | 0.92 | CALCR (0.59) | CALCRLCALCRF2NPY2RNPY4R | |
| SCHEMBL30726592 | 0.89 | CALCR (0.62) | CALCRLCALCRF2NPY2RNPY4R | |
| SCHEMBL29993925 | 0.88 | CALCRL (0.62) | CALCRLSLC6A2RAMP1F2BACE1 | |
| SCHEMBL29479825 | 0.88 | MAPK8 (0.59) | CALCRLCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30512639 | 0.87 | CALCRL (0.59) | CALCRLSLC6A2RAMP1F2BACE1 | |
| SCHEMBL29591691 | 0.87 | SLC6A2 (0.58) | SLC6A2NTSR2NTSR1SORT1 | |
| SCHEMBL30123059 | 0.87 | CALCRL (0.61) | CALCRLSLC6A2RAMP1CALCRBACE1 | |
| SCHEMBL30880893 | 0.86 | MAPK8 (0.54) | CALCRLCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31233779 | 0.86 | SLC6A2 (0.66) | CALCRLSLC6A2NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | CALCRL 2202/4885SLC6A2 4537/4885RAMP1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.